Make your money go further for just 25p per day

AIM IHT

Novacyt: on these numbers, the cheapest stock on the market

Novacyt Versalab image

AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?


Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year:


Revenue +2400% to €311.6m (£277.0m) including revenue in the second half of the year of €239.2m (£213.7m).
EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll.
Cash at 31 December 2020 was…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on Novacyt SA

Impressive results | Trading well | Little to cheer

01/05/2025 · Company Insights

News covered here includes our assessment of excellent results from a provider of compliance and e-learning…


A refocused business delivers

30/09/2022 · Company Insights

Having survived a near death experience several years ago, a manufacturer of specialist industrial equipment covered…


More Company Insights

Another acquisition | Trading well | Space contract

Stonking Small Caps: update sees shares fall back

15/05/2025 · Gamma Communications

US approval | Successful sale | Angling success

Sign-up to our free email updates

SIGN UP